Cargando…

Postoperative clinical outcomes of patients with thymic epithelial tumors after over-3-year follow-up at a single-center

BACKGROUND: To evaluate postoperative clinical outcomes and analyze influencing factors for patients with thymic epithelial tumors over 3 years after operation. METHODS: Patients with thymic epithelial tumors (TETs) who underwent surgical treatment in the Department of Thoracic Surgery at Beijing Ho...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiao, Peng, Tian, Wen-Xin, Wu, Fan-Juan, Liu, Yu-Xing, Wu, Jiang-Yu, Sun, Yao-Guang, Yu, Han-Bo, Huang, Chuan, Wu, Qing-Jun, Ma, Chao, Li, Dong-Hang, Tong, Hong-Feng, Li, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9942311/
https://www.ncbi.nlm.nih.gov/pubmed/36810094
http://dx.doi.org/10.1186/s13019-023-02169-6
_version_ 1784891472251715584
author Jiao, Peng
Tian, Wen-Xin
Wu, Fan-Juan
Liu, Yu-Xing
Wu, Jiang-Yu
Sun, Yao-Guang
Yu, Han-Bo
Huang, Chuan
Wu, Qing-Jun
Ma, Chao
Li, Dong-Hang
Tong, Hong-Feng
Li, Jun
author_facet Jiao, Peng
Tian, Wen-Xin
Wu, Fan-Juan
Liu, Yu-Xing
Wu, Jiang-Yu
Sun, Yao-Guang
Yu, Han-Bo
Huang, Chuan
Wu, Qing-Jun
Ma, Chao
Li, Dong-Hang
Tong, Hong-Feng
Li, Jun
author_sort Jiao, Peng
collection PubMed
description BACKGROUND: To evaluate postoperative clinical outcomes and analyze influencing factors for patients with thymic epithelial tumors over 3 years after operation. METHODS: Patients with thymic epithelial tumors (TETs) who underwent surgical treatment in the Department of Thoracic Surgery at Beijing Hospital from January 2011 to May 2019 were retrospectively enrolled in the study. Basic patient information, clinical, pathological, and perioperative data were collected. Patients were followed up by telephone interviews and outpatient records. Statistical analyses were performed using SPSS version 26.0. RESULTS: A total of 242 patients (129 men, 113 women) with TETs were included in this study, of which 150 patients (62.0%) were combined with myasthenia gravis (MG) and 92 patients (38.0%) were not. 216 patients were successfully followed up and their complete information was available. The median follow-up period was 70.5 months (range, 2–137 months). The 3-year overall survival (OS) rate of the whole group was 93.9%, and the 5-year OS rate was 91.1%. The 3-year relapse-free survival (RFS) rate of the whole group was 92.2%, and the 5-year relapse-free survival rate was 89.8%. Multivariable COX regression analysis indicated that recurrence of thymoma was an independent risk factor for OS. Younger age, Masaoka-Koga stage III + IV, and TNM stage III + IV were independent risk factors for RFS. Multivariable COX regression analysis indicated that Masaoka-Koga staging III + IV, WHO type B + C were independent risk factors for postoperative improvement of MG. For patients with MG, the postoperative complete stable remission (CSR) rate was 30.5%. And the result of multivariable COX regression analysis showed that thymoma patients with MG with Osserman staging IIA + IIB + III + IV were not prone to achieving CSR. Compared with patients without MG, MG was more likely to develop in patients with WHO classification type B, and patients with myasthenia gravis were younger, with longer operative duration, and more likely to develop perioperative complications. CONCLUSIONS: The 5-year overall survival rate of patients with TETs was 91.1% in this study. Younger age and advanced stage were independent risk factors for RFS of patients with TETs, and recurrence of thymoma were independent risk factors for OS. In patients with MG, WHO classification type B and advanced stage were independent predictors of poor outcomes of MG treatment after thymectomy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13019-023-02169-6.
format Online
Article
Text
id pubmed-9942311
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-99423112023-02-22 Postoperative clinical outcomes of patients with thymic epithelial tumors after over-3-year follow-up at a single-center Jiao, Peng Tian, Wen-Xin Wu, Fan-Juan Liu, Yu-Xing Wu, Jiang-Yu Sun, Yao-Guang Yu, Han-Bo Huang, Chuan Wu, Qing-Jun Ma, Chao Li, Dong-Hang Tong, Hong-Feng Li, Jun J Cardiothorac Surg Research BACKGROUND: To evaluate postoperative clinical outcomes and analyze influencing factors for patients with thymic epithelial tumors over 3 years after operation. METHODS: Patients with thymic epithelial tumors (TETs) who underwent surgical treatment in the Department of Thoracic Surgery at Beijing Hospital from January 2011 to May 2019 were retrospectively enrolled in the study. Basic patient information, clinical, pathological, and perioperative data were collected. Patients were followed up by telephone interviews and outpatient records. Statistical analyses were performed using SPSS version 26.0. RESULTS: A total of 242 patients (129 men, 113 women) with TETs were included in this study, of which 150 patients (62.0%) were combined with myasthenia gravis (MG) and 92 patients (38.0%) were not. 216 patients were successfully followed up and their complete information was available. The median follow-up period was 70.5 months (range, 2–137 months). The 3-year overall survival (OS) rate of the whole group was 93.9%, and the 5-year OS rate was 91.1%. The 3-year relapse-free survival (RFS) rate of the whole group was 92.2%, and the 5-year relapse-free survival rate was 89.8%. Multivariable COX regression analysis indicated that recurrence of thymoma was an independent risk factor for OS. Younger age, Masaoka-Koga stage III + IV, and TNM stage III + IV were independent risk factors for RFS. Multivariable COX regression analysis indicated that Masaoka-Koga staging III + IV, WHO type B + C were independent risk factors for postoperative improvement of MG. For patients with MG, the postoperative complete stable remission (CSR) rate was 30.5%. And the result of multivariable COX regression analysis showed that thymoma patients with MG with Osserman staging IIA + IIB + III + IV were not prone to achieving CSR. Compared with patients without MG, MG was more likely to develop in patients with WHO classification type B, and patients with myasthenia gravis were younger, with longer operative duration, and more likely to develop perioperative complications. CONCLUSIONS: The 5-year overall survival rate of patients with TETs was 91.1% in this study. Younger age and advanced stage were independent risk factors for RFS of patients with TETs, and recurrence of thymoma were independent risk factors for OS. In patients with MG, WHO classification type B and advanced stage were independent predictors of poor outcomes of MG treatment after thymectomy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13019-023-02169-6. BioMed Central 2023-02-21 /pmc/articles/PMC9942311/ /pubmed/36810094 http://dx.doi.org/10.1186/s13019-023-02169-6 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Jiao, Peng
Tian, Wen-Xin
Wu, Fan-Juan
Liu, Yu-Xing
Wu, Jiang-Yu
Sun, Yao-Guang
Yu, Han-Bo
Huang, Chuan
Wu, Qing-Jun
Ma, Chao
Li, Dong-Hang
Tong, Hong-Feng
Li, Jun
Postoperative clinical outcomes of patients with thymic epithelial tumors after over-3-year follow-up at a single-center
title Postoperative clinical outcomes of patients with thymic epithelial tumors after over-3-year follow-up at a single-center
title_full Postoperative clinical outcomes of patients with thymic epithelial tumors after over-3-year follow-up at a single-center
title_fullStr Postoperative clinical outcomes of patients with thymic epithelial tumors after over-3-year follow-up at a single-center
title_full_unstemmed Postoperative clinical outcomes of patients with thymic epithelial tumors after over-3-year follow-up at a single-center
title_short Postoperative clinical outcomes of patients with thymic epithelial tumors after over-3-year follow-up at a single-center
title_sort postoperative clinical outcomes of patients with thymic epithelial tumors after over-3-year follow-up at a single-center
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9942311/
https://www.ncbi.nlm.nih.gov/pubmed/36810094
http://dx.doi.org/10.1186/s13019-023-02169-6
work_keys_str_mv AT jiaopeng postoperativeclinicaloutcomesofpatientswiththymicepithelialtumorsafterover3yearfollowupatasinglecenter
AT tianwenxin postoperativeclinicaloutcomesofpatientswiththymicepithelialtumorsafterover3yearfollowupatasinglecenter
AT wufanjuan postoperativeclinicaloutcomesofpatientswiththymicepithelialtumorsafterover3yearfollowupatasinglecenter
AT liuyuxing postoperativeclinicaloutcomesofpatientswiththymicepithelialtumorsafterover3yearfollowupatasinglecenter
AT wujiangyu postoperativeclinicaloutcomesofpatientswiththymicepithelialtumorsafterover3yearfollowupatasinglecenter
AT sunyaoguang postoperativeclinicaloutcomesofpatientswiththymicepithelialtumorsafterover3yearfollowupatasinglecenter
AT yuhanbo postoperativeclinicaloutcomesofpatientswiththymicepithelialtumorsafterover3yearfollowupatasinglecenter
AT huangchuan postoperativeclinicaloutcomesofpatientswiththymicepithelialtumorsafterover3yearfollowupatasinglecenter
AT wuqingjun postoperativeclinicaloutcomesofpatientswiththymicepithelialtumorsafterover3yearfollowupatasinglecenter
AT machao postoperativeclinicaloutcomesofpatientswiththymicepithelialtumorsafterover3yearfollowupatasinglecenter
AT lidonghang postoperativeclinicaloutcomesofpatientswiththymicepithelialtumorsafterover3yearfollowupatasinglecenter
AT tonghongfeng postoperativeclinicaloutcomesofpatientswiththymicepithelialtumorsafterover3yearfollowupatasinglecenter
AT lijun postoperativeclinicaloutcomesofpatientswiththymicepithelialtumorsafterover3yearfollowupatasinglecenter